SC-0191

N/A

Report date: 2023/12/07 10:19:29
NME

Base Information

Drug NameSC-0191
Drug Alias NameSC0191SC-0191
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase WEE1 inhibitors
TargetsSerine/threonine-protein kinase WEE1
Therapy Area/IndicationsSolid tumoursOvarian NeoplasmsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShijiazhuang Zhikang Hongren New Drug Development Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Zhongshan HospitalWuxi BioCity
Inactive CompaniesShijiazhuang Zhikang Hongren New Drug Development Co Ltd
Active IndicationsSolid tumoursOvarian NeoplasmsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A